University Malaya Medical Centre

Kuala Lumpur, Malaysia

23 recruiting

Showing 120 of 43 trials

Recruiting

A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants

Diabetes Mellitus, Type 2
Novo Nordisk A/S400 enrolled6 locationsNCT07532863
Recruiting
Phase 3

A Study to Learn About the Effects of Felzartamab Infusions on Adults With Immunoglobulin A Nephropathy (IgAN)

Immunoglobulin A Nephropathy (IgAN)
Biogen454 enrolled244 locationsNCT06935357
Recruiting
Phase 3

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma (DLBCL)
Regeneron Pharmaceuticals904 enrolled155 locationsNCT06091865
Recruiting
Phase 3

A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression

Primary IgA Nephropathy
Hoffmann-La Roche428 enrolled204 locationsNCT05797610
Recruiting
Phase 3

A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosclerosis (FSGS)

Focal Segmental Glomerulosclerosis
Boehringer Ingelheim286 enrolled277 locationsNCT07220083
Recruiting
Phase 3

LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

Metabolic Dysfunction-Associated Steatohepatitis
Boehringer Ingelheim1,590 enrolled447 locationsNCT06632457
Recruiting
Phase 3

The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis

Bronchiectasis
Boehringer Ingelheim1,755 enrolled494 locationsNCT06872892
Recruiting
Phase 3

LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

Metabolic dysfunction-associated steatohepatitis (MASH)Liver Fibrosis
Boehringer Ingelheim1,800 enrolled526 locationsNCT06632444
Recruiting
Phase 3

EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)

Kidney Disease, Chronic
Boehringer Ingelheim11,000 enrolled475 locationsNCT06531824
Recruiting
Phase 3

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

Cardiovascular DiseasesHypertensionDiabetes Mellitus, Type 2
Boehringer Ingelheim11,800 enrolled1155 locationsNCT07064473
Recruiting
Phase 2Phase 3

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

Atherosclerotic Cardiovascular Disease in Patients With ESKD
CSL Behring3,110 enrolled547 locationsNCT05485961
Recruiting
Phase 2Phase 3

A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

Crohn Disease
Janssen Research & Development, LLC1,092 enrolled363 locationsNCT07196722
Recruiting
Phase 2

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

Carcinoma, Non-Small Cell Lung
Janssen Research & Development, LLC520 enrolled110 locationsNCT05498428
Recruiting
Phase 3

A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis

Colitis Ulcerative
Janssen Research & Development, LLC882 enrolled393 locationsNCT07196748
Recruiting
Phase 3

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Colorectal Neoplasms
Janssen Research & Development, LLC700 enrolled247 locationsNCT06750094
Recruiting
Phase 3

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Colorectal Neoplasms
Janssen Research & Development, LLC1,000 enrolled237 locationsNCT06662786
Recruiting
Phase 1Phase 2

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC287 enrolled56 locationsNCT06385080
Recruiting
Phase 1Phase 2

A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer

Advanced or Metastatic Colorectal Cancer
Janssen Research & Development, LLC225 enrolled53 locationsNCT05379595
Recruiting
Phase 3

A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic
Janssen Research & Development, LLC600 enrolled169 locationsNCT07438496
Recruiting
Phase 3

A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant
Janssen Research & Development, LLC800 enrolled136 locationsNCT07225946